The results from the published studies on the association between hypoxia-inducible factor-1(Hif-1/HIF-1) polymorphisms and cancer risk are conflicting. The common 1790G/A rs11549467) genetic polymorphism has been reported to be functional and may contribute to genetic susceptibility to cancers. However, the association between 1790G/A (rs11549467) and cancer risk remains inconclusive.
Cancer is one of the leading causes of death in the world. It has become a worldwide public health problem [1] . The exact mechanism of carcinogenesis is not yet fully elucidated [2] . Recently, it has become clear that genetic variation contributes to the development and progression of cancer [2, 3] . However, due to various reasons, including considerable heterogeneity of the disease, the identification of susceptibility genes is difficult and most associations have not been replicated.
One of the most important features of tumors is hypoxia. Intratumoral hypoxia occurs when cells are located further from a functional blood vessel than is required for adequate diffusion of oxygen, resulting in rapid tumor cell proliferation and developing abnormal blood vessels [4] . Hypoxia conditions in tumor tissues induce a molecular response, which drives the activation of transcription factors. Among these, hypoxia-inducible factor-1(Hif-1/HIF-1) plays an essential role in adaptive responses to reduced oxygen levels [5, 6] .
Hif-1/HIF-1 is a dimeric protein complex, consisting of α and β subunits. The activity of Hif-1/HIF-1 is regulated predominantly through the stability of the subunit [7] . Koshiji et al. demonstrated that Hif-1/HIF-1 (PASD8) inhibits the DNA mismatch repair system (MSH2 and MSH6), which is responsible for genetic instability [8] . Other researchers have also reported that hypoxia down regulates the expression of DNA double-stranded break repair genes [9, 10] [11, 12] . These data support the concept that defective DNA repair pathways cause genomic instability within the tumor microenvironment. PASD8 (Hif-1/HIF-1) is overexpressed in >90% of colon, lung and prostate cancers, whereas no expression was detected in corresponding normal tissues [13] , indicating a role of Hif-1/ HIF-1 in cancer. It is over expressed in several human cancers, such as head-neck, colon, breast, stomach, pancreas, prostate, kidney, esophagus, endometrial, and non-small-cell lung cancer [14] [15] [16] [17] [18] [19] . The target genes of Hif-1/HIF-1 are particularly relevant to cancer, encoding angiogenic factors, proliferation/ survival factors, glucose transporters and glycolytic enzymes [20] . As such, variability in this protein is likely to influence individual risk to this pathology.
A number of investigators have studied the possible association between the Hif-1/HIF-1 polymorphisms and cancer risk, but the results have been conflicting [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . Thus, the association between the Hif-1/HIF-1 polymorphisms and cancers requires further investigation. In an attempt to clarify this inconsistency, we have combined all the published studies of hospital and population up to August.2013 in a meta-analysis to give a comprehensive picture of the role of Hif-1/HIF-1α gene using multiple research methods and models.
In this study, a comprehensive meta-analysis was performed on previous reports to investigate the association of Hif-1/HIF-1α 1790G/A (rs11549467) polymorphisms with all cancers, different kinds of cancers, and different kinds of populations.
Materials and methods
Search strategy and data extraction. In this meta-analysis, a comprehensive literature research of the US National Library of Medicine's PubMed database, ISI Web of Knowledge, Medline, Embase and Google Scholar Search (update to August,2013) was conducted using the search terms including "Hif-1/HIF-1α" or "hypoxia-inducible factor-1" or "1790G/A" or "rs11549467" or "A588T (Ala588Thr, G1790A, rs11549467)" , "polymorphisms" or "variation" or "mutation" or "SNP" , "tumour" or "tumor" or "cancer" or "neoplasm" or "phyma" or "oncoma" or "knub" or "carcinoma" or "malignancy", and the combined phrases in order to obtain all genetic studies on the relationship of 1790G/A polymorphism and cancers. We also used a hand search of references of original studies or reviewed articles on this topic to identify additional studies. Eligible studies were selected according to the following explicit inclusion criteria: (1) a case control study on the association between 1790G/A polymorphism and cancer risk, (2)detailed number of different genotypes for estimating an odds ratio (OR) with 95% confidence interval (CI), (3) when several publications reported on the same population data, the largest or most complete study was chosen, (4) cases with carcinomas were diagnosed by histopathology, (5) animal studies, case reports, review articles, abstracts, editorials, reports with incomplete data, and studies based on pedigree data were excluded (Fig. 1 ). For each eligible study, the following information was recorded: the first author's name, the year of publication, patients, ethnicity, genotyping methods, sources of control, racial descent of the study population, genotype and allele distributions and main results of each study.
Statistical analysis. The strength of relationship between 1790G/A polymorphism and cancer was assessed by using crude OR with 95% CI. We examined the association between the 1790G/A polymorphism and cancer risk using the following genetic models: homozygote comparison (AA vs. GG), heterozygote comparison (AG vs. GG), dominant genetic model (AA/AG vs. GG), recessive genetic model (AA vs. AG/GG) and additive model (A vs. G). Firstly, we checked the Hardy-Weinberg equilibrium (HWE) in controls for each study. Then we performed Q-test for evaluating the heterogeneity [39] . Fixed effects model was used to pool the data when the P-value of Q-test ≥0.05; otherwise, random effects model was selected [40] . I 2 was also used to assess the heterogeneity in this meta-analysis. If I 2 > 50%,the heterogeneity exists [41] . We also performed sensitivity analysis and subgroup analysis to explore the reason of heterogeneity. Both funnel plot and Egger's test were used to assess the publication bias (P<0.05 was representative of statistical significance) [42] . All statistical analysis were performed using STATA 12.0 software and Review Manager 5.2.
Results
Eligible studies. Overall,26 relevant studies involving 6337 cases and 9302 controls were selected in this metaanalysis [21, 26, 27, 29, 30, 32, [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] . The main characteristics of these studies were shown in Table 1 . Genotype and allele distributions of 1790G/A polymorphism among cancer cases and controls and P value of HWE in controls were shown in Table 1 and 2. All studies were case-control studies, including three oral squamous cell carcinoma (OSCC) studies [46, 51, 59] , three prostate cancer studies [29, 44, 60] , three renal cell carcinoma studies [21, 49, 57] , three breast cancer studies [30, 32, 50] , two gynecologic carcinoma studies [27, 53] , two colorectal studies [26, 62] , two pancreatic cancer studies [55, 58] , three lung cancer studies [47, 54, 56] and the others(including head and neck squamous cell carcinoma(HNSCC) [43] , transitional cell carcinoma of the bladder [45] , hepatocellular carcinoma [52] , gastric cancer [52] , glottic cancer [61] ). Cancers were histological or pathological in most studies. There were fourteen studi es [32, 43, 45 studies, while hospital-based controls were carried out in 17 studies. All studies were reported in English. The genotyping methods contained the classic polymerase chain reactionrestriction fragment length polymorphism ( PCR-RFLP) assay, PCR-sequencing, PCR-LDR, SnaPShot and Taqman. The genotype distributions of controls were all in agreement with HWE except for one studie not estimable [27] .
Meta-analysis. Overall, as shown in Table 3 , we observed that the 1790G/A(rs11549467) polymorphism increased the cancer risk in the homozygote (AA vs. GG, OR=4.37[2.61-7.33]) (Fig.2) , heterozygote model (AG vs. GG, OR=1.39[1.06-1.82]) (Fig.3) , dominant genetic model (OR=1.46[1.11-1.92]) (Fig.4) (Fig.6 ) when all the eligible studies were pooled into the meta-analysis. In the heterozygote comparison, dominant genetic and additive models, all the P values of Q-test were lower than 0.05 and I 2 values were higher than 50%. So we performed the sensitivity analysis by deleting one single study from overall pooled analysis each time to check the influence of the removed data. However, the results revealed that no extreme sensitive study changed the between-study heterogeneities.
We then evaluated the effects of the 1790G/A(rs11549467) polymorphism according to specific cancer types, different ethnicities, different detection method and different sources of control. As shown in Table 3 . According to the source of controls, signification effects in all genetic models were observed in hospital-based studies; while in population-based studies, significant association was not observed in any genetic model. According to the detection method, signification effects in most genetic models were observed in PCR-RFLP subgroup; while in other subgroup, significant association was not observed in any genetic model. 
Discussion
This meta-analysis of 26 studies involving 6337 cases and 9302 controls was conducted in order to yield a valid conclusion concerning the potential association between 1790G/A (rs11549467) polymorphism and cancer risk. HIF-1 plays a major role in cancer progression and metastasis through activation of various genes that are linked to regulation of angiogenesis, cell survival, and energy metabolism [63, 64] . The Hif-1/HIF-1 was previously found to be implicated in the development and progression of cancer [63, 64] . In 2009, Zhao T et al. [65] have done a meta-analysis on the relationship between Hif-1/HIF-1 and cancers, but their study only referred to the case-control studies before 2009. The polymorphisms analyzed in the present study consist of G to A nucleotide substitutions at positions 1790 of the exon 12 of the Hif-1/HIF-1. Because a study by Tanimoto [64] showed both of the substitutions displayed an increased transactivation capacity of Hif-1/HIF-1α in vitro, the presence of the variant alleles might be associated with increased cancer susceptibility. However, studies focusing on the association of the Hif-1/HIF-1 polymorphism with cancer susceptibility had controversial conclusions [21, 26, 27, 29, 30, 32, [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] . The lack of concordance across many of these studies reflects limitation in the studies, such as small sample sizes, ethnic difference and research methodology and so on. Meta-analysis is a powerful tool for summarizing the results from different studies by producing a single estimate of the major effect with enhanced precision.
In our analysis, there was significant association between this polymorphism and oral squamous cell carcinoma (OSCC) risk under the homozygote model. Patients carrying the A allele at position 1790 of the exon 12 of the Hif-1/HIF-1 had more cancer risk than did patients homozygous for the G allele. Besides, for oral squamous cell carcinoma (OSCC), pancreatic cancer and lung cancer, the associations were more significant in the recessive model than in the dominant model. These results suggested that homozygous AA had stronger effects on an individual's phenotype than heterozygous AG. So individuals with AA genotype could have higher risk of the three cancer type than that with AG genotype. The pooled effects for homozygote comparison and dominant model comparison suggested a significant association between the 1790G/A (rs11549467) polymorphism and a decreased gynecologic cancer risk. Furthermore, We found that Caucasian with AA genotype had higher risk of cancer compared to Asian under the homozygote and recessive models. Inconsistency between the two ethnicities can be explained by the possibility that different ethnic groups live with multiple life styles and environmental factors. And different populations carry different genotype and/or allele frequencies of this locus polymorphism which may lead to various degrees of cancer susceptibility. In our meta-analysis, we also observed inconsistent results between hospital-based studies and population-based studies. Our results show that controls in hospital-based studies are more representative of general population than controls from population-based studies. Several factors such as environmental factors and genetic backgrounds might contribute to the discrepancy.
There were some limitations in our meta-analysis. First, sample size in any given cancer was not sufficiently large, which could increase the probability of false positive or false negative results. It might be difficult to get a concrete conclusion if the number of included studies in subgroup was few. Besides, studies involved in different ethnicities were warranted to estimate the effects of this functional polymorphism on cancer risk. Second, due to the original data of the eligible studies was unavailable, it was difficult for us to evaluate the roles of some special environmental factors and lifestyles such as diet, alcohol consumption, and smoking status in developing cancer. Third, the influence of bias in the present analysis could not be completely excluded because positive results are supposed to be published much more quickly than articles with "negatives" results.
Conclusions
Our meta-analysis suggested that the Hif-1/HIF-1 1790G/ A(rs11549467) genetic polymorphism may contribute to the susceptibility of cancers except gynecologic cancer, especially in homozygote comparison (AA vs. GG) and recessive genetic model (AA vs. AG/GG) among Caucasian population, and this SNP was significantly associated with the lung cancer, pancreatic cancer and oral squamous cell carcinoma (OSCC). The phenomenon also indicates that the SNP functions as a recessive mutation, which needs to be verified or linked with functional studies. Large well designed epidemiological studies are needed to validate our findings. 
